Metastatic Breast Cancer Clinical Trial
Official title:
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
Verified date | May 2012 |
Source | Veeda Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a Phase II, open-label, non-randomized study in patients with locally advanced or
metastatic breast cancer.
Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated
every 8 weeks for response. Patients will continue to receive study treatment until disease
progression or unacceptable toxicity.
Status | Completed |
Enrollment | 72 |
Est. completion date | May 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: To be eligible for the study, patients must fulfill all of the following criteria: - Patients must have signed an IRB-approved informed consent. - Patients must have histologically or pathologically confirmed and documented locally advanced or metastatic breast cancer. Patients may be Her2+ or Her2-. - Patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension as >2 cm with conventional techniques or as >1 cm with spiral CT scan. Palpable disease is acceptable. - Patients must be >18 years of age. - Patients must have an ECOG Performance Status of 0 or 1 (see Appendix I). - Patients' estimated life expectancy must be at least 12 weeks. - Patients may have received prior adjuvant chemotherapy for breast cancer, including taxane-containing regimens, provided this treatment was completed at least 12 months prior to enrollment. - Patients may have received prior radiation (except for radiation to the entire pelvis), provided that less than 25% of the bone marrow has been treated, and the patient has recovered from the acute toxic effects of treatment prior to trial enrollment. Prior radiation treatment must have been completed at least 4 weeks prior to enrollment. Lesions that have been irradiated in the advanced disease setting may not be included as sites of measurable disease. - Patients may have received prior hormonal, AI (aromatase inhibitors) therapy, or immunotherapy. All hormonal, AI, and immunotherapy must have been terminated prior to enrollment. - Patients must have adequate liver function defined as: for patients with no liver metastases, aspartate transaminase (AST), alanine transaminase (ALT), and bilirubin levels can be up to 1.5 times the upper limit of normal (ULN). For patients with liver metastases, ALT, AST, and bilirubin levels can be up to 2.5 times the ULN. - Patients must have adequate renal function defined as: creatinine < 2mg/dL or calculated creatinine clearance must be > 40mL/min. - Patients must have adequate bone marrow function, including absolute neutrophil count (ANC) ³1500/µL, platelet count ³100,000/µL, and hemoglobin ³9 g/dL. - Patients must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal for at least 12 months. - Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter. - Patients must be willing and able to comply with scheduled visits, treatment plan and laboratory testing, and be accessible for follow-up. Exclusion Criteria: Any of the following criteria will make the patient ineligible to participate in this study: - Patients who have received prior chemotherapy for the treatment of metastatic breast cancer. - Patients who have received prior Abraxane. - Patients who have a history of hypersensitivity to taxanes or any of the components in taxanes or Abraxane. - Patients with serious intercurrent medical or psychiatric illness. - Patients with a second primary malignancy, except carcinoma in situ of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated >5 years previously and with no evidence of recurrence. - Patients with only non-measurable disease, defined as all other lesions including small lesions and truly non-measurable lesions. - Patients with parenchymal or leptomeningeal brain metastases. - Patients planning to receive any concurrent therapy to treat metastatic or locally advanced breast cancer during the study treatment period. - Any patient who is pregnant or lactating. |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Veeda Oncology | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Veeda Oncology | Celgene Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the response rate of Abraxane given weekly as first-line treatment for patients with locally advanced or metastatic breast cancer. | unk | No | |
Secondary | To assess time to progression (TTP), overall survival (OS), and toxicities of Abraxane as first-line treatment for patients with locally advanced or metastatic breast cancer. | unk | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04872608 -
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02506556 -
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05534438 -
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03368729 -
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04103853 -
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Active, not recruiting |
NCT03147287 -
Palbociclib After CDK and Endocrine Therapy (PACE)
|
Phase 2 | |
Not yet recruiting |
NCT06062498 -
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04095390 -
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04432454 -
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
|
Phase 2 | |
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
Completed |
NCT02924883 -
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
|
Phase 2 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Completed |
NCT01942135 -
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
|
Phase 3 | |
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT01401959 -
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT04720664 -
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
|
Phase 2 |